Immunicom, based in San Diego, CA, develops non-pharmaceutical approaches including a blood-filtering technology intended to treat stage IV metastatic cancer as well as inflammatory and autoimmune diseases. The company’s platform is designed to address a wide variety of cancer types, including tumors that have not responded to drug- and biologic-based immunotherapies, and may produce fewer side effects. Immunicom secured an additional $1.85M toward its Series B investment round, bringing the Series B to $12.85M and total capital raised to $21.85M. The recent funding was an incremental addition to an ongoing Series B. Amir Jafri is the company’s Founder and CEO. The company also hired Raju Chauhan as Vice President of Program Management to provide guidance and oversight to internal and customer-facing initiatives. Immunicom is a medical technology company in San Diego focused on developing innovative, non-pharmaceutical approaches for treating cancer, inflammatory diseases, and autoimmune diseases. Its core product, Immunopheresis™, is a proprietary blood-filtering device and outpatient treatment analogous to dialysis that extracts tumor-produced proteins from the bloodstream. The therapy aims to revitalize a cancer patient’s immune system to naturally fight tumor cells without introducing new chemicals, proteins, or antibodies. The company is led by founder and CEO Amir Jafri. Proceeds from the recent financing will fund a 170-patient, randomized, multi-center triple-negative breast cancer clinical trial that began May 31 and will accelerate expansion of global strategic partnerships. The company has raised $20M in total capital to date.

Total raised

$13M

Funding rounds

2

Latest round

Series B

Latest activity

Oct 2019